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Summary. Muscarinic cholinergic receptors and choline 
acetyltransferase (CHAT) activity were studied in post- 
mortem brain tissue from patients with Hunt ington's  dis- 
ease and matched control subjects. In comparison with 
controls, reductions in ChAT activity were found in the 
hippocampus, but not in the temporal  cortex in Hunting- 
ton's disease. Patients with Hunt ington's  disease showed 
reduced densities of the total number  of muscarinic re- 
ceptors and of M-2 receptors in the hippocampus while 
the density of M-1 receptors was unaltered. Muscarinic 
receptor binding was unchanged in the temporal  cortex. 
These results indicate a degeneration in Hunt ington's  
disease of the septo-hippocampal cholinergic pathway, 
but no impairment of the innominato-cortical choliner- 
gic system. 
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Introduction 
Hunt ington's  disease is characterized clinically by chore- 
iform movements and progressive dementia. Dement ia  
in Alzheimer's disease and Parkinson's disease appears 
to be associated with degeneration of subcortico-cortical 
cholinergic systems [5, 7, 9]. While acetylcholine-con- 
taining neurons are damaged in the basal ganglia in Hun- 
t ington's disease [2, 10], the status of the cholinergic af- 
ferent projections to the neocortex and hippocampus i
less clear. We have examined choline acetyltransferase 
(CHAT) activity and muscarinic cholinergic receptor 
binding in the temporal  cortex (Brodmann area 38) and 
hippocampus in Hunt ington's  disease. 
Patients and methods 
Brain tissue was obtained at autopsy from 12 patients with neuro- 
pathologically confirmed Huntington's disease and from 12 matched 
* Present address and address for offprint requests: Universit~its- 
Nervenklinik, Ffichsleinstrasse 15, W-8700 Wtirzburg, Federal Re- 
public of Germany 
control subjects with no evidence of neurological or psychiatric dis- 
ease. All patients with Huntington's chorea had suffered from ad- 
vanced forms of the disease and had been demented according to 
DSM III criteria [1]. They had received neuroleptic medication up 
to the time of death. Controls had not received any drugs that are 
known to affect the central nervous ystem. Using washed mem- 
brane homogenates, aturation analysis was performed for the 
3 total number of muscarinic receptors with [ H]-quinuclidinylbenzi- 
late, for M-1 receptors with [3H]-pirenzepine and for M-2 recep- 
tors with [3H]-oxotremorine-M. Non-specific binding was defined 
by atropine. Protein concentration and ChAT activity were mea- 
sured by standard techniques (details from K.W.L.). 
Results 
In comparison with controls, reductions in ChAT activ- 
ity were found in the hippocampus but not in the tem- 
Table 1. Mean (SEM) ChAT activity and maximal receptor bind- 
ing in the temporal cortex and hippocampus. * P < 0.05 (Wilco- 
xon's rank-sum test); ChAT activity in nmol/h/mg protein; recep- 
tor binding as Bmax in fmol/mg protein 
Control Huntington's 
disease 
No. of brains 12 
Sex 2 F, l0 M 
Age (years) 68.7 (2.5) 
Death to brain removal (h) 28.4 (5.6) 
ChAT activity 
- in temporal cortex 4.5 (0.3) 
- in hippocampus 12.7 (0.9) 
[3H] -quinuclidinylbenzilate binding 
- in temporal cortex 861 (32) 
- in hippocampus 364 (12) 
[3H]-pirenzepine binding 
- in temporal cortex 651 (20) 
- in hippocampus 235 (13) 
[3H]-oxotremorine-M-binding 
- in temporal cortex 183 (12) 
- in hippocampus 74 (6) 
12 
5F, 7M 
64.2 (2.1) 
30.1 (4.4) 
4.2 (0.3) 
8.1 (0.8)* 
811 (26) 
280 (12)* 
580 (18) 
197 (15) 
194 (10) 
39 (3)* 
104 
poral cortex in Huntington's disease (Table 1). Patients 
with Huntington's disease showed reduced densites of 
the total number of muscarinic receptors and of M-2 re- 
ceptors measured by specific binding of [3H]-quinucli- 
dinylbenzilate and [3H]-oxotremorine-M in the hippo- 
campus while the density of M-1 receptors, as identified 
by specific [3H]-pirenzepine binding, was unchanged. 
Muscarinic receptor binding was unaltered in the tem- 
poral cortex. Alterations in the equilibrium dissociation 
constants (KD) were not observed. 
Discussion 
The reduction in ChAT activity and in muscarinic M-2 
receptors, which are thought to be located mainly pre- 
synaptically, indicates a degeneration of the cholinergic 
pathway from the septum to the hippocampus. This is 
supported by decreased ChAT activity in septal nuclei 
[10]. The present results of unaltered cortical ChAT ac- 
tivity and putatively pre-synaptic M-2 receptors uggest 
that the ascending cholinergic system from the substan- 
tia innominata to the neocortex is not damaged in Hun- 
tington's disease. This is consistent with previous reports 
showing a preservation of neurons in the nucleus basalis 
of Meynert [3, 6]. Dementia is associated with neuronal 
damage or loss in the nucleus basalis in Alzheimer's dis- 
ease and Parkinson's disease [8]. The findings in Hun- 
tington's disease, however, indicate that damage to this 
region is not a prerequisite for the development of de- 
mentia. The cognitive impairment in Huntington's dis- 
ease may be related to hippocampal deficits and damage 
to neuronal systems within the basal ganglia, although it 
cannot be ruled out that the dementia might stem direct- 
ly from cortical atrophy [4]. 
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